• AstraZeneca And Daiichi Sankyo Withdraw EU Marketing Application For Datopotamab Deruxtecan

    Source: NASDAQ US Markets / 24 Dec 2024 02:40:25   America/New_York

    (RTTNews) - British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said that they have voluntarily withdrawn their marketing authorisation application (MAA) in the European Union for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with https://www.nasdaq.com/articles/astrazeneca-and-daiichi-sankyo-withdraw-eu-marketing-application-datopotamab-deruxtecan
Share on,